Files
Abstract
Certain antipsychotic medications, particularly clozapine, have been associated with a decrease in the differences in white matter, cognitive performance, and psychosis symptoms typical for individuals with psychosis syndromes. This project takes a multimodal approach to assessing these differences based on medication group via diffusion tensor imaging (DTI), the Brief Assessment of Cognition in Schizophrenia, saccade data, dosage, and symptom measures. This project included 984 participants from the Bipolar-Schizophrenia Network for Intermediate Phenotypes (B-SNIP) consortium, and variables were assessed by medication group using ANOVAs and CCA. Results indicated similarities between participants taking clozapine and healthy individuals in white matter tracts related to aspects of cognition such as goal-oriented behavior and executive functioning. Similarities between these groups were also evident for some saccade tasks and cognitive performance. These results have clinical implications for psychiatric treatment strategies and may help elucidate some of the potential effects and benefits of clozapine.